How many drugs treat Spasticity?

Drug Landscape tracks 10 marketed treatments for Spasticity (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/spasticity.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Spasticity — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spasticity (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Spasticity, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Botox	ONABOTULINUMTOXINA	Allergan	Acetylcholine Release Inhibitor [EPC]	SNAP-25	2010-01-01
Zanaflex	TIZANIDINE	Legacy Pharma Usa	Central alpha-2 Adrenergic Agonist	Nischarin	1996-01-01
Ryanodex	DANTROLENE	Ph Health	Skeletal Muscle Relaxant	Ryanodine receptor 1	1974-01-01
Maolate	CHLORPHENESIN CARBAMATE	Pfizer			1965-01-01
Valium	diazepam	Generic (originally Roche)	Benzodiazepine [EPC]	Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2	1963-11-15
Skelaxin	METAXALONE	Pfizer	Muscle Relaxant [EPC]		1962-01-01
Soma	CARISOPRODOL	Mylan Speciality Lp	Muscle Relaxant [EPC]		1959-01-01
Parafon Forte Dsc	CHLORZOXAZONE	Johnson & Johnson	Muscle Relaxant [EPC]	Nitric oxide synthase, endothelial	1958-01-01
Robaxin	METHOCARBAMOL	Hikma	Muscle Relaxant [EPC]	Carbonic anhydrase 1	1957-01-01
Norgesic	caffeine	Hikma	Central Nervous System Stimulant [EPC]	Adenosine receptor A2a	1948-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Spasticity:

Cite this brief

Drug Landscape (2026). Spasticity — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/spasticity. Accessed 2026-06-10.

Spasticity full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing